Friday, July 10, 2026

pharma · CXCR4 · Uterine Cervical Neoplasms

Zhongnan Hospital

Zhongnan Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include CXCR4, Uterine Cervical Neoplasms. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent recor

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
2
Drugs
5
Patents
0
Clinical program

68Ga-pentixafor

Unknown · small molecule · CXCR4

68Ga-pentixafor for CXCR4 is a Unknown program (small_molecule) at Zhongnan Hospital with 1 ClinicalTrials.gov record(s).

← All Zhongnan Hospital projects Unknown small molecule active

Internal code ZNYYHYXK0002

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Zhongnan Hospital
Phase
Unknown
Modality
small_molecule
Indication
CXCR4
Status
active
Trials
1

Clinical trials